Literature DB >> 20861258

BST-2 diminishes HIV-1 infectivity.

Jianyong Zhang1, Chen Liang.   

Abstract

Bone marrow stromal cell antigen 2 (BST-2, also known as tetherin/CD317/HM1.24) inhibits the release of human immunodeficiency virus type 1 (HIV-1) and other enveloped viruses by tethering virus particles to the cell surface. In this study, we provide evidence not only that the yield of cell-free HIV-1 particles is significantly reduced by BST-2 but also that the infectivity of these progeny virions is severely impaired. The lowered virion infectivity is due to the accumulation of pr55 Gag precursor and the p40Gag intermediates as well as to the loss of a mature core in the majority of HIV-1 particles. These data suggest that, in addition to impeding the release of HIV-1 particles from host cells, BST-2 may also interfere with the activation of viral protease and, as a result, impairs viral Gag processing as well as maturation of HIV-1 particles.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861258      PMCID: PMC2976413          DOI: 10.1128/JVI.01228-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.

Authors:  H G Göttlinger; T Dorfman; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

2.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.

Authors:  T Klimkait; K Strebel; M D Hoggan; M A Martin; J M Orenstein
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

Review 3.  HIV-1 gag proteins: diverse functions in the virus life cycle.

Authors:  E O Freed
Journal:  Virology       Date:  1998-11-10       Impact factor: 3.616

4.  Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein.

Authors:  F Maldarelli; M Y Chen; R L Willey; K Strebel
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

5.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Tetherin restricts productive HIV-1 cell-to-cell transmission.

Authors:  Nicoletta Casartelli; Marion Sourisseau; Jerome Feldmann; Florence Guivel-Benhassine; Adeline Mallet; Anne-Geneviève Marcelin; John Guatelli; Olivier Schwartz
Journal:  PLoS Pathog       Date:  2010-06-17       Impact factor: 6.823

9.  Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology.

Authors:  Sabine Kupzig; Viktor Korolchuk; Ruth Rollason; Anna Sugden; Andrew Wilde; George Banting
Journal:  Traffic       Date:  2003-10       Impact factor: 6.215

10.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

View more
  19 in total

1.  Assembly and replication of HIV-1 in T cells with low levels of phosphatidylinositol-(4,5)-bisphosphate.

Authors:  Kazuaki Monde; Vineela Chukkapalli; Akira Ono
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 2.  Innate immunity in acute HIV-1 infection.

Authors:  Persephone Borrow
Journal:  Curr Opin HIV AIDS       Date:  2011-09       Impact factor: 4.283

3.  BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1).

Authors:  Philip H Jones; Martina Maric; Marisa N Madison; Wendy Maury; Richard J Roller; Chioma M Okeoma
Journal:  Virology       Date:  2013-02-12       Impact factor: 3.616

4.  HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer.

Authors:  Rebecca Rose; Susanna L Lamers; David J Nolan; Ekaterina Maidji; N R Faria; Oliver G Pybus; James J Dollar; Samuel A Maruniak; Andrew C McAvoy; Marco Salemi; Cheryl A Stoddart; Elyse J Singer; Michael S McGrath
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

5.  A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo.

Authors:  Bradley S Barrett; Diana S Smith; Sam X Li; Kejun Guo; Kim J Hasenkrug; Mario L Santiago
Journal:  PLoS Pathog       Date:  2012-03-22       Impact factor: 6.823

6.  β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.

Authors:  Hanna-Mari Tervo; Stefanie Homann; Ina Ambiel; Joëlle V Fritz; Oliver T Fackler; Oliver T Keppler
Journal:  Retrovirology       Date:  2011-02-10       Impact factor: 4.602

7.  Tetherin restricts direct cell-to-cell infection of HIV-1.

Authors:  Björn D Kuhl; Richard D Sloan; Daniel A Donahue; Tamara Bar-Magen; Chen Liang; Mark A Wainberg
Journal:  Retrovirology       Date:  2010-12-24       Impact factor: 4.602

Review 8.  Tetherin and its viral antagonists.

Authors:  Björn D Kuhl; Vicky Cheng; Mark A Wainberg; Chen Liang
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-11       Impact factor: 4.147

Review 9.  Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factors.

Authors:  Clare Jolly
Journal:  Virology       Date:  2011-01-17       Impact factor: 3.616

10.  TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+ T cells across the virological synapse.

Authors:  Fabien P Blanchet; Romaine Stalder; Magdalena Czubala; Martin Lehmann; Laura Rio; Bastien Mangeat; Vincent Piguet
Journal:  Retrovirology       Date:  2013-01-11       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.